{"schema_version":"secwatch.filing_event.v1","accession":"0001654954-24-008613","form_type":"8-K","ticker":"VTAK","cik":"0001716621","company_name":"Catheter Precision, Inc.","filed_at":"2024-07-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.241927+00:00","generated_at":"2026-05-31T23:31:29.448383+00:00","sec_items":["2.02","3.02","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Catheter Precision reports Q2 revenue of $94,840; approves 1-for-10 reverse stock split","bullets":["Preliminary Q2 2024 revenue $94,840, including first LockeT sales ($40,500) and VIVO ($54,340).","Six-month 2024 revenue $176,923; 15% sequential quarter-over-quarter growth.","Board approved 1-for-10 reverse stock split effective July 15, 2024; shares reduce from 8.4M to ~839K.","Series A Preferred conversion issued 814,228 common shares on July 1, 2024.","New CCO Marie Claude Jaques hired in May; sales pipeline growing."],"urls":{"canonical":"https://secwatch.observer/filing/0001654954-24-008613","json":"https://secwatch.observer/filing/0001654954-24-008613.json","markdown":"https://secwatch.observer/filing/0001654954-24-008613.md","text":"https://secwatch.observer/filing/0001654954-24-008613.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1716621/000165495424008613/0001654954-24-008613-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1716621/000165495424008613/rmed_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T23:31:29.448383+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}